S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:BIIB

Biogen Stock Forecast, Price & News

$267.12
-1.65 (-0.61 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$266.09
Now: $267.12
$271.98
50-Day Range
$266.51
MA: $278.48
$291.48
52-Week Range
$221.56
Now: $267.12
$374.99
Volume1.14 million shs
Average Volume1.66 million shs
Market Capitalization$42.29 billion
P/E Ratio7.82
Dividend YieldN/A
Beta0.54
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More
Biogen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Employees7,400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.38 billion
Cash Flow$36.84 per share
Book Value$73.93 per share

Profitability

Net Income$5.89 billion

Miscellaneous

Market Cap$42.29 billion
Next Earnings Date10/21/2020 (Confirmed)
OptionableOptionable
$267.12
-1.65 (-0.61 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock price been impacted by Coronavirus?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has decreased by 9.2% and is now trading at $267.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Biogen?

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen
.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, October 21st 2020.
View our earnings forecast for Biogen
.

How can I listen to Biogen's earnings call?

Biogen will be holding an earnings conference call on Wednesday, October 21st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $8.03 by $2.23. The biotechnology company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.44 billion. Biogen had a net margin of 40.91% and a return on equity of 50.10%. During the same quarter last year, the company posted $9.15 earnings per share.
View Biogen's earnings history
.

How will Biogen's stock buyback program work?

Biogen declared that its board has approved a stock buyback plan on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its stock is undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

What price target have analysts set for BIIB?

31 equities research analysts have issued 12-month price targets for Biogen's shares. Their forecasts range from $228.00 to $396.00. On average, they expect Biogen's share price to reach $311.82 in the next year. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Biogen
.

Are investors shorting Biogen?

Biogen saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 2,830,000 shares, a decrease of 23.3% from the September 15th total of 3,690,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is presently 2.5 days. Currently, 1.8% of the shares of the stock are sold short.
View Biogen's Short Interest
.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Mr. Michel Vounatsos, CEO & Director (Age 58, Pay $5.72M)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 63, Pay $1.99M)
  • Dr. Alfred W. Sandrock Jr., Exec. VP of R&D (Age 62, Pay $1.87M)
  • Mr. Chirfi Guindo, Exec. VP of Global Product Strategy & Commercialization (Age 54, Pay $1.32M)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 56)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.23%), DNB Asset Management AS (0.16%), Saratoga Research & Investment Management (0.15%), PGGM Investments (0.12%), Envestnet Asset Management Inc. (0.12%) and Assenagon Asset Management S.A. (0.08%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Wedge Capital Management L L P NC, Gateway Investment Advisers LLC, Factory Mutual Insurance Co., Hexavest Inc., Redpoint Investment Management Pty Ltd, Bowling Portfolio Management LLC, and Nissay Asset Management Corp Japan ADV. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen
.

Which major investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., 6 Meridian, Denali Advisors LLC, Rhenman & Partners Asset Management AB, Envestnet Asset Management Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen
.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $267.12.

How big of a company is Biogen?

Biogen has a market capitalization of $42.29 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.